Therefore, angiotensin‐converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may mitigate and reduce the risk of ACS and MI through the upregulation of cardioprotective ACE2 with the regulation of the balance of Ang II/Ang‐17 axis, which prevents inflammation and thrombosis.123. The gene discussed is AGT; the disease is myocardial infarction.